Lipigon Pharmaceuticals AB (LPGO) - Total Assets
Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) holds total assets worth Skr11.49 Million SEK (≈ $1.24 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lipigon Pharmaceuticals AB - Total Assets Trend (2017–2025)
This chart illustrates how Lipigon Pharmaceuticals AB's total assets have evolved over time, based on quarterly financial data. Also see market value of Lipigon Pharmaceuticals AB for the company's overall valuation and market capitalisation.
Lipigon Pharmaceuticals AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Lipigon Pharmaceuticals AB's total assets of Skr11.49 Million consist of 97.8% current assets and 2.2% non-current assets. Review Lipigon Pharmaceuticals AB balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 88.9% |
| Accounts Receivable | Skr1.02 Million | 8.9% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Lipigon Pharmaceuticals AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LPGO stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lipigon Pharmaceuticals AB's current assets represent 97.8% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 88.9% of total assets in 2025, down from 90.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 8.9% of total assets.
Lipigon Pharmaceuticals AB Competitors by Total Assets
Key competitors of Lipigon Pharmaceuticals AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Lipigon Pharmaceuticals AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.14 | 2.07 | 23.62 |
| Quick Ratio | 3.14 | 2.07 | 23.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr7.66 Million | Skr7.54 Million | Skr59.07 Million |
Lipigon Pharmaceuticals AB - Advanced Valuation Insights
This section examines the relationship between Lipigon Pharmaceuticals AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.28 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -22.5% |
| Total Assets | Skr11.49 Million |
| Market Capitalization | $97.81K USD |
Valuation Analysis
Below Book Valuation: The market values Lipigon Pharmaceuticals AB's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lipigon Pharmaceuticals AB's assets decreased by 22.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lipigon Pharmaceuticals AB (2017–2025)
The table below shows the annual total assets of Lipigon Pharmaceuticals AB from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr11.49 Million ≈ $1.24 Million |
-22.51% |
| 2024-12-31 | Skr14.82 Million ≈ $1.60 Million |
-55.89% |
| 2023-12-31 | Skr33.60 Million ≈ $3.62 Million |
+210.67% |
| 2022-12-31 | Skr10.82 Million ≈ $1.16 Million |
-63.25% |
| 2021-12-31 | Skr29.43 Million ≈ $3.17 Million |
+93.07% |
| 2020-12-31 | Skr15.24 Million ≈ $1.64 Million |
+374.83% |
| 2019-12-31 | Skr3.21 Million ≈ $345.45K |
+1326.67% |
| 2018-12-31 | Skr225.00K ≈ $24.21K |
-99.99% |
| 2017-12-31 | Skr1.77 Billion ≈ $190.54 Million |
-- |
About Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which… Read more